Total Payments
$11,825
2023 Payments
$54.88
Companies
15
Transactions
32
Medicare Patients
19,593
Medicare Billing
$7.5M
Payment Breakdown by Category
Consulting$7,450 (63.0%)
Other$3,905 (33.0%)
Food & Beverage$281.55 (2.4%)
Education$139.81 (1.2%)
Gifts$48.00 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $7,450 | 6 | 63.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,905 | 4 | 33.0% |
| Food and Beverage | $281.55 | 16 | 2.4% |
| Education | $139.81 | 5 | 1.2% |
| Gift | $48.00 | 1 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $4,110 | 2 | $0 (2021) |
| Janssen Biotech, Inc. | $2,340 | 3 | $0 (2021) |
| Exelixis Inc. | $1,554 | 2 | $0 (2020) |
| PFIZER INC. | $1,263 | 7 | $0 (2022) |
| F. Hoffmann-La Roche AG | $1,185 | 2 | $0 (2019) |
| Seattle Genetics, Inc. | $1,000 | 1 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $129.76 | 4 | $0 (2023) |
| Sysmex Inostics Inc | $91.42 | 4 | $0 (2017) |
| Tosoh Bioscience, Inc. | $48.00 | 1 | $0 (2019) |
| Clovis Oncology, Inc. | $32.20 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $54.88 | 3 | ASD Specialty Healthcare, LLC ($22.56) |
| 2022 | $1,288 | 3 | PFIZER INC. ($1,250) |
| 2021 | $6,527 | 7 | AstraZeneca Pharmaceuticals LP ($4,110) |
| 2020 | $1,522 | 3 | Exelixis Inc. ($1,470) |
| 2019 | $1,318 | 4 | F. Hoffmann-La Roche AG ($1,185) |
| 2018 | $10.51 | 1 | Celgene Corporation ($10.51) |
| 2017 | $1,105 | 11 | Seattle Genetics, Inc. ($1,000) |
All Payment Transactions
32 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 02/21/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.09 | General |
| Category: Oncology | ||||||
| 02/10/2023 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $13.23 | General |
| 02/01/2023 | ASD Specialty Healthcare, LLC | — | Food and Beverage | In-kind items and services | $22.56 | General |
| 08/23/2022 | Pharmacyclics LLC, an AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $12.05 | General |
| Category: ONCOLOGY | ||||||
| 05/17/2022 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.49 | General |
| Category: Hematology | ||||||
| 03/14/2022 | PFIZER INC. | INLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,250.00 | General |
| Category: ONCOLOGY | ||||||
| 12/23/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: Oncology | ||||||
| 12/23/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: Oncology | ||||||
| 11/01/2021 | Janssen Biotech, Inc. | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $780.00 | General |
| Category: Oncology | ||||||
| 06/01/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $65.49 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/21/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 04/20/2021 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 11/16/2020 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: Oncology | ||||||
| 09/25/2020 | Clovis Oncology, Inc. | Rubraca (Drug) | Education | In-kind items and services | $32.20 | General |
| Category: Oncology | ||||||
| 07/13/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $19.69 | General |
| Category: Oncology | ||||||
| 11/27/2019 | Tosoh Bioscience, Inc. | FER, ST AIA-PACK (Medical Supply) | Gift | In-kind items and services | $48.00 | General |
| Category: Immunoassay | ||||||
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $944.46 | General |
| Category: BioOncology | ||||||
| 06/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $240.94 | General |
| Category: BioOncology | ||||||
| 02/15/2019 | Exelixis Inc. | — | Food and Beverage | In-kind items and services | $84.30 | General |
| 11/13/2018 | Celgene Corporation | Abraxane (Drug) | Education | In-kind items and services | $10.51 | General |
| Category: Oncology | ||||||
| 12/28/2017 | Sysmex Inostics Inc | — | Food and Beverage | Cash or cash equivalent | $28.50 | General |
| 12/04/2017 | Sysmex Inostics Inc | — | Food and Beverage | Cash or cash equivalent | $17.77 | General |
| 11/20/2017 | PFIZER INC. | SUTENT (Drug), XALKORI, INLYTA | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 10/31/2017 | Sysmex Inostics Inc | — | Food and Beverage | Cash or cash equivalent | $39.53 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 82 | 4,522 | 169,079 | $7.2M | $1.5M |
| 2022 | 81 | 4,665 | 147,343 | $6.6M | $1.4M |
| 2021 | 85 | 5,046 | 152,733 | $8.4M | $2.0M |
| 2020 | 87 | 5,360 | 176,185 | $10.6M | $2.6M |
Total Patients
19,593
Total Services
645,340
Medicare Billing
$7.5M
Procedure Codes
342
All Medicare Procedures & Services
342 procedure records from CMS Medicare Utilization — Page 1 of 14
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 20 | 12,400 | $1.7M | $501,490 | 29.4% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 11 | 9,641 | $720,440 | $206,122 | 28.6% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 12 | 4,140 | $455,400 | $154,290 | 33.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 37 | 7,140 | $399,840 | $132,292 | 33.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 361 | 932 | $292,648 | $86,112 | 29.4% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 2,440 | $561,200 | $56,260 | 10.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 156 | 451 | $303,974 | $43,237 | 14.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 69 | 309 | $182,619 | $41,402 | 22.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 34 | 36 | $243,000 | $38,666 | 15.9% |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2023 | 19 | 4,260 | $191,700 | $26,730 | 13.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 26 | 24,000 | $96,000 | $21,215 | 22.1% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 11 | 180 | $181,980 | $15,701 | 8.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 56 | 35,190 | $175,950 | $13,909 | 7.9% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 32 | 33 | $30,558 | $13,768 | 45.1% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 15 | 59 | $40,061 | $11,584 | 28.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 69 | 75 | $224,175 | $11,315 | 5.0% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 25 | 6,890 | $41,340 | $9,490 | 23.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 256 | 881 | $73,123 | $9,093 | 12.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 121 | 418 | $62,700 | $8,959 | 14.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 74 | 74 | $39,812 | $8,766 | 22.0% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 12 | 1,530 | $55,080 | $8,431 | 15.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 267 | 973 | $25,298 | $8,165 | 32.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 270 | 989 | $61,318 | $7,508 | 12.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 97 | 157 | $53,380 | $7,468 | 14.0% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 116 | 388 | $56,260 | $6,974 | 12.4% |
About Dr. Gary Macvicar, MD
Dr. Gary Macvicar, MD is a Hematology healthcare provider based in Peoria, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487633251.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Macvicar, MD has received a total of $11,825 in payments from pharmaceutical and medical device companies, with $54.88 received in 2023. These payments were reported across 32 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($7,450).
As a Medicare-enrolled provider, Macvicar has provided services to 19,593 Medicare beneficiaries, totaling 645,340 services with total Medicare billing of $7.5M. Data is available for 4 years (2020–2023), covering 342 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Peoria, IL
- Active Since 01/11/2006
- Last Updated 10/04/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1487633251
Products in Payments
- ERLEADA (Drug) $2,340
- IMFINZI (Biological) $2,055
- LYNPARZA (Drug) $2,055
- Cabometyx (Drug) $1,470
- INLYTA (Drug) $1,250
- TECENTRIQ (Biological) $1,185
- OPDIVO (Biological) $85.18
- FER, ST AIA-PACK (Medical Supply) $48.00
- Rubraca (Drug) $32.20
- REBLOZYL (Biological) $25.49
- OPDUALAG (Drug) $19.09
- SUTENT (Drug) $13.41
- IMBRUVICA (Drug) $12.05
- Abraxane (Drug) $10.51
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.